Safety was demonstrated through a combination of genotypic analysis, phenotypic data, and published clinical trials.
Image courtesy of Kaneka
Kaneka Americas Holding Inc. announced that its Intensive G.I. probiotic formulation is now self-affirmed GRAS (generally recognized as safe). According to Fumiki Aoki, PhD, business development director for Kaneka’s probiotics division, safety was demonstrated through a combination of genotypic analysis, phenotypic data, and published clinical trials. “Whole Genome Sequencing was performed to establish the identity of the strains and allow the use of bioinformatics for genomic analysis, which demonstrated the absence of a genetic basis for any safety concerns,” explained Aoki, in a press release. “Published clinical trials for the strains and species were evaluated for evidence of safety and the absence of adverse effects.”
“We are committed to establishing Kaneka’s Floradapt probiotic portfolio as one of the most innovative and efficacious products for a variety of health targets, as supported by scientific evidence,” said Mike Kolifrath, vice president, sales and marketing of Kaneka’s probiotics division, in a press release. “This milestone significantly advances our leadership in the probiotic space and will offer our Intensive G. I. formula access to consumer brands searching for G.I. probiotics with unique mechanisms of action, while removing any doubts on the safety and benefits of the strains.”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.